


## CNX-2006

Cat. No.:	HY-13897
CAS No.:	1375465-09-0
Molecular Formula:	C <sub>26</sub> H <sub>27</sub> F <sub>4</sub> N <sub>7</sub> O <sub>2</sub>
Molecular Weight:	545.53
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    2 years -20°C    1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 52 mg/mL (95.32 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.8331 mL	9.1654 mL	18.3308 mL
	5 mM	0.3666 mL	1.8331 mL	3.6662 mL
	10 mM	0.1833 mL	0.9165 mL	1.8331 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

Description	CNX-2006 is a mutant-selective and irreversible EGFR inhibitor with an IC <sub>50</sub> below 20 nM for EGFR <sup>T790M</sup> .	
IC <sub>50</sub> & Target	EGFR <sup>T790M</sup> 20 nM (IC <sub>50</sub> )	EGFR <sup>L858R/T790M</sup>
In Vitro	<p>CNX-2006 inhibits EGFR-T790M cells growth up to 1000-fold more compared to wild-type EGFR cells. EGFR inhibition is observed in cells harbouring the T790M mutation at IC<sub>50</sub> values below 20 nM after 1 hour exposure to the drug. CNX-2006 also significantly reduces the volume of tumor spheres derived from H1975 cells<sup>[1]</sup>. CNX-2006 exhibits specificity and potent activity against T790M. The drug also shows activity against uncommon EGFR mutations including G719S, L861Q, an exon 19 insertion mutant (I744-K745insKIPVAL), and T854A, but not an exon 20 insertion (H773-V774HVDup). In an in vitro resistance model, CNX-2006 significantly inhibits the emergence of resistant cells. Chronic exposure to escalating doses of CNX-2006 fails to select for and/or enhance T790M-mediated resistance using PC-9 or HCC827 cells (both harboring exon 19 deletions), or PC-9/ER and HCC827/ER cells with existing T790M and resistance to erlotinib<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

---

## REFERENCES

- [1]. Galvani E, et al. Abstract 3244: Role of epithelial-mesenchymal transition (EMT) in sensitivity to CNX-2006, a novel mutant-selective EGFR inhibitor which overcomes in vitro T790M-mediated resistance in NSCLC. CNX-2006, a novel mutant-selective EGFR inhib
- [2]. Ohashi K, et al. Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance in vitro. [abstract]. In: Proceedings of the 104th Annual Meet
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA